GSDMD and hepatocellular carcinoma: Gasdermin D (GSDMD) also contributes to increased PD-L1 expression in HCC by activating the Ca2+/HDACs/STAT1 signaling pathway and inducing K+ efflux, which inhibits the cGAS pathway and reduces type I interferon production, weakening ICB efficacy[79].